SynthesisHormones (Athens, Greece)2025
Thyrotropin-secreting pituitary adenomas in pregnancy: insights from a systematic review.
Synthesis in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyrotropin-secreting pituitary adenomas (TSHomas) are rare neuroendocrine tumors that account for less than 1% of all pituitary adenomas. Managing TSHomas during pregnancy presents a unique challenge, balancing physiological thyroid changes with risks of tumor progression and maternal-fetal complications. This systematic review analyzes reported cases of TSHomas diagnosed before and during pregnancy, focusing on clinical presentation, diagnostic difficulties, treatment, and maternal-fetal outcomes. A systematic literature search in the PubMed, Scopus, and Cochrane Library databases identified nine case reports of pregnant patients with TSHomas between 1993 and 2024. Common symptoms included hyperthyroidism-related manifestations (55%), galactorrhea (33%), and anxiety (44%). Diagnostic challenges arose from pregnancy-related thyroid changes requiring careful interpretation of trimester-specific thyroid function tests and imaging findings. Management strategies included somatostatin analogs (SSAs), antithyroid drugs, and transsphenoidal surgery (TSS). SSAs were discontinued during pregnancy but resumed in select cases due to tumor progression. Surgery was generally deferred until postpartum unless significant mass effects warranted urgent intervention. TSS was performed in one case during pregnancy due to mass effect symptoms. All pregnancies resulted in live births except one elective termination. No severe maternal or fetal complications were reported. The findings emphasize the importance of a multidisciplinary approach in managing TSHomas during pregnancy. Early recognition, tailored medical therapy, and close endocrine-obstetric collaboration are crucial to optimize outcomes. Differentiation from resistance to thyroid hormone (RTH) is critical for accurate diagnosis. While SSAs and delayed surgical intervention appear safe and effective, further research is required to refine diagnostic and therapeutic protocols and to investigate the molecular pathogenesis of this rare condition.
Indexed as
Identifiers
40760324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.